Skip Navigation


Rheumatology Advance Access originally published online on May 5, 2006
Rheumatology 2006 45(6):784-785; doi:10.1093/rheumatology/kel135
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/6/784    most recent
kel135v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by De Vita, S.
Right arrow Articles by Quartuccio, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by De Vita, S.
Right arrow Articles by Quartuccio, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTER TO THE EDITOR

Rituximab as possible first-line therapy for glomerulonephritis in HCV-related mixed cryoglobulinaemia

Salvatore De Vita and Luca Quartuccio

Rheumatology Clinic, DPMSC, University of Udine, Italy

Correspondence to: Salvatore De Vita, MD, Professor of Rheumatology, Chief, Rheumatology Clinic, DPMSC, University of Udine, Udine 33100, Italy.E-mail: salvatore.devita@med.uniud.it

The first 10% of the full text of this article appears below.

SIR, Bruchfeld and colleagues either misunderstood or ignored the key message of our report [1], and reiterate their position statement on the role of anti-viral therapy in glomerulonephritis associated with hepatitis C virus (HCV) infection-related mixed cryoglobulinaemia (MC) syndrome [2], as already done with a previous Italian report in which less enthusiastic conclusions on this topic were reported [3]. The colleagues state that anti-viral therapy will and should remain the first-line therapy for HCV-related MC syndrome with nephritis.

. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
L. Quartuccio, M. Fabris, S. Salvin, M. Isola, F. Soldano, E. Falleti, C. A. Beltrami, V. De Re, and S. De Vita
Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis
Rheumatology, November 1, 2007; 46(11): 1657 - 1661.
[Abstract] [Full Text] [PDF]